Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, withdrew its plans for an initial public offering on Tuesday. It had filed to raise $25 million by offering 4.2 million units at a price range of $5.50 to $6.50,...read more
Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, announced terms for its IPO on Friday. The company is currently listed on the SIX Swiss Exchange (RLF) and the OTC (RLFTD). The Genève, Switzerland-...read more
Six small deals priced this past week, though only three met the criteria for our 2022 IPO stats. Pipeline activity picked up with three new IPO filings, including a biotech that plans to raise $150 million, as well as amendments from some notable issuers on...read more
Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering. The company is currently listed on the SIX Swiss Exchange (RLF). Relief ...read more
Swiss rare disease biopharma Relief Therapeutics withdraws $25 million US IPO
Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, withdrew its plans for an initial public offering on Tuesday. It had filed to raise $25 million by offering 4.2 million units at a price range of $5.50 to $6.50,...read more
Swiss rare disease biopharma Relief Therapeutics sets terms for $25 million US IPO
Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, announced terms for its IPO on Friday. The company is currently listed on the SIX Swiss Exchange (RLF) and the OTC (RLFTD). The Genève, Switzerland-...read more
US IPO Weekly Recap: Summer IPO market marches on with more small deals
Six small deals priced this past week, though only three met the criteria for our 2022 IPO stats. Pipeline activity picked up with three new IPO filings, including a biotech that plans to raise $150 million, as well as amendments from some notable issuers on...read more
Swiss rare disease biopharma Relief Therapeutics files for a $20 million US IPO
Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering. The company is currently listed on the SIX Swiss Exchange (RLF). Relief ...read more